CA2311409A1 - Traitement aux anticorps anti-erbb2 - Google Patents

Traitement aux anticorps anti-erbb2 Download PDF

Info

Publication number
CA2311409A1
CA2311409A1 CA002311409A CA2311409A CA2311409A1 CA 2311409 A1 CA2311409 A1 CA 2311409A1 CA 002311409 A CA002311409 A CA 002311409A CA 2311409 A CA2311409 A CA 2311409A CA 2311409 A1 CA2311409 A1 CA 2311409A1
Authority
CA
Canada
Prior art keywords
cancer
erbb2
antibody
article
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002311409A
Other languages
English (en)
Other versions
CA2311409C (fr
Inventor
Steven Shak
Virginia E. Paton
Susan D. Hellmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech, Inc.
Steven Shak
Virginia E. Paton
Susan D. Hellmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22088358&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2311409(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech, Inc., Steven Shak, Virginia E. Paton, Susan D. Hellmann filed Critical Genentech, Inc.
Priority to CA2730373A priority Critical patent/CA2730373A1/fr
Publication of CA2311409A1 publication Critical patent/CA2311409A1/fr
Application granted granted Critical
Publication of CA2311409C publication Critical patent/CA2311409C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne le traitement de troubles caractérisés par la surexpression de ErbB2. L'invention concerne, en particulier, le traitement de patients humains susceptibles d'être atteint d'un cancer surexprimant ErbB2 ou chez qui ce cancer a été diagnostiqué, à l'aide d'une combinaison d'anticorps anti-ErbB2 et d'un agent chimiothérapeutique autre que les anthracyclines, par exemple la doxorubicine ou l'épirubicine.
CA2311409A 1997-12-12 1998-12-10 Traitement aux anticorps anti-erbb2 Expired - Lifetime CA2311409C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2730373A CA2730373A1 (fr) 1997-12-12 1998-12-10 Traitement d'un cancer presentant une surexpression de erbb2 avec des anticorps anti-erbb2 et un agent chimiotherapique hormonal

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6934697P 1997-12-12 1997-12-12
US60/069,346 1997-12-12
PCT/US1998/026266 WO1999031140A1 (fr) 1997-12-12 1998-12-10 TRAITEMENT AUX ANTICORPS ANTI-ErbB2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2730373A Division CA2730373A1 (fr) 1997-12-12 1998-12-10 Traitement d'un cancer presentant une surexpression de erbb2 avec des anticorps anti-erbb2 et un agent chimiotherapique hormonal

Publications (2)

Publication Number Publication Date
CA2311409A1 true CA2311409A1 (fr) 1999-06-24
CA2311409C CA2311409C (fr) 2011-04-12

Family

ID=22088358

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2730373A Abandoned CA2730373A1 (fr) 1997-12-12 1998-12-10 Traitement d'un cancer presentant une surexpression de erbb2 avec des anticorps anti-erbb2 et un agent chimiotherapique hormonal
CA2311409A Expired - Lifetime CA2311409C (fr) 1997-12-12 1998-12-10 Traitement aux anticorps anti-erbb2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2730373A Abandoned CA2730373A1 (fr) 1997-12-12 1998-12-10 Traitement d'un cancer presentant une surexpression de erbb2 avec des anticorps anti-erbb2 et un agent chimiotherapique hormonal

Country Status (18)

Country Link
US (11) US7846441B1 (fr)
EP (3) EP2275450A1 (fr)
JP (7) JP2002508397A (fr)
KR (7) KR20120062942A (fr)
CN (2) CN1269839C (fr)
AR (1) AR020051A1 (fr)
AU (1) AU1908199A (fr)
BR (1) BR9815363A (fr)
CA (2) CA2730373A1 (fr)
DK (1) DK1037926T3 (fr)
ES (1) ES2450922T3 (fr)
HK (2) HK1030784A1 (fr)
IL (4) IL136201A0 (fr)
NO (2) NO20002957L (fr)
NZ (1) NZ504597A (fr)
TR (1) TR200001689T2 (fr)
WO (1) WO1999031140A1 (fr)
ZA (1) ZA9811162B (fr)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6972170B1 (en) 1997-12-01 2005-12-06 Sloan-Kettering Institute For Cancer Research Markers for prostate cancer
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6333348B1 (en) 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
EP1187632B1 (fr) * 1999-05-14 2008-12-03 Genentech, Inc. TRAITEMENT AVEC DES ANTICORPS ANTI-ErbB2
WO2000077258A1 (fr) * 1999-06-10 2000-12-21 Sloan-Kettering Institute For Cancer Research Marqueurs du cancer de la prostate
KR100850389B1 (ko) * 1999-06-25 2008-08-04 제넨테크, 인크. 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
EP1189634B1 (fr) * 1999-06-25 2007-02-28 Genentech, Inc. Traitement du cancer de la prostate a l'aide des anticorps anti-erbb2
BRPI0017590B8 (pt) 1999-06-25 2021-05-25 Genentech Inc conjugado de maitansinoide - anticorpo anti-erbb, e formulação farmacêutica
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CA2373721C (fr) * 1999-07-02 2013-10-15 Genentech, Inc. Composes se liant a her2
GB9917012D0 (en) * 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
ES2277683T3 (es) 1999-07-23 2007-07-16 Glaxo Group Limited Combinacion de anticuerpo anti-ep-cam con un agente quimioterapeutico.
EP1246597B1 (fr) 1999-08-03 2015-01-14 The Ohio State University Polypeptides et polynucleotides ameliorant la reactivite immunitaire a la proteine her-2
ATE438411T1 (de) * 1999-08-27 2009-08-15 Genentech Inc Dosierung für die behandlung mit anti erbb2- antikörpern
EP2266607A3 (fr) 1999-10-01 2011-04-20 Immunogen, Inc. Des immunoconjugués pour le traitement des cancers.
US7285382B2 (en) 2000-01-25 2007-10-23 Genentech, Inc. Compositions and methods for treatment of cancer
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
WO2001070268A1 (fr) * 2000-03-22 2001-09-27 Glaxo Group Limited Produit pharmaceutique comprenant un agent bloquant le cycle cellulaire et anticorps
PL360153A1 (en) * 2000-05-15 2004-09-06 Pharmacia & Upjohn S.P.A. Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
MXPA02011379A (es) * 2000-05-19 2003-06-06 Genentech Inc Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb.
GB0017635D0 (en) * 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
WO2002087618A1 (fr) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Methode de prevention et de traitement du cancer
WO2002087619A1 (fr) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Methode de prevention et de traitement du cancer
AU2003222664A1 (en) * 2002-04-18 2003-11-03 Genencor International, Inc. Production of functional antibodies in filamentous fungi
CA2487600C (fr) 2002-05-30 2011-07-05 Toray Industries, Inc. Adsorbants pour substance immunosuppressive, colonne de circulation extracorporelle, et procedes de traitement du cancer
AU2002951853A0 (en) * 2002-10-04 2002-10-24 Commonwealth Scientific And Industrial Research Organisation Crystal structure of erbb2 and uses thereof
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
KR20120068807A (ko) 2004-07-22 2012-06-27 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101115849A (zh) * 2004-12-07 2008-01-30 健泰科生物技术公司 选择her抑制剂疗法的患者
KR20170134771A (ko) 2005-01-21 2017-12-06 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
MX2007009566A (es) * 2005-02-09 2009-02-16 Genentech Inc Inhibicion de la difusion de la her2 con antagonistas de la metaloproteasa de matriz.
UA95902C2 (ru) 2005-02-23 2011-09-26 Дженентек, Инк. Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
WO2006096861A2 (fr) * 2005-03-08 2006-09-14 Genentech, Inc. Methodes permettant d'identifier des tumeurs sensibles au traitement par des inhibiteurs de dimerisation her (hdi)
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
EP1912680B1 (fr) 2005-06-15 2014-11-26 The Ohio State University Research Foundation Peptides her-2
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US20100168393A1 (en) * 2005-10-11 2010-07-01 Big Glucose Ltd. Antibody Polypeptide Libray Screening and Selected Antibody Polypeptides
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
CN101505792B (zh) 2006-08-21 2012-10-03 霍夫曼-拉罗奇有限公司 使用抗-vegf抗体的肿瘤疗法
ES2477497T3 (es) 2007-03-02 2014-07-17 Genentech, Inc. Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo
US8557588B2 (en) * 2007-03-27 2013-10-15 Schlumberger Technology Corporation Methods and apparatus for sampling and diluting concentrated emulsions
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
WO2008150485A2 (fr) * 2007-05-29 2008-12-11 Wyeth Compositions thérapeutiques et procédés
EP2171090B1 (fr) 2007-06-08 2013-04-03 Genentech, Inc. Marqueurs d'expression de gène de résistance tumorale à un traitement par inhibiteur her2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2219602A1 (fr) * 2007-11-15 2010-08-25 Amgen, Inc Préparation aqueuse de protéine de stimulation de l'érythropoïèse stabilisée par des antioxydants pour une administration par voie parentérale
EP2235536A4 (fr) 2007-12-20 2011-05-04 Lab Corp America Holdings Procédés de diagnostic du her-2
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8734795B2 (en) * 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
MX340724B (es) 2008-11-22 2016-07-22 Genentech Inc Terapia anti-angiogenesis para el tratamiento del cancer de mama.
SG177252A1 (en) 2008-12-01 2012-03-29 Lab Corp America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
BRPI1007321A2 (pt) 2009-01-15 2018-07-10 Laboratory Corp America Holdings métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
UA106070C2 (uk) 2009-03-20 2014-07-25 Дженентек, Інк. Антитіло, що специфічно зв'язується з egfr і her3
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
SG183333A1 (en) 2010-02-18 2012-09-27 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (fr) 2010-05-19 2011-11-24 Genentech, Inc. Prédiction de réponses à un inhibiteur de her
CA2800769C (fr) 2010-05-27 2021-11-02 Genmab A/S Anticorps monoclonaux contre l'epitope de her2
EP3539988A3 (fr) 2010-05-27 2019-12-04 Genmab A/S Anticorps monoclonaux contre her2
TW201204388A (en) 2010-06-18 2012-02-01 Genentech Inc Anti-Axl antibodies and methods of use
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CN101974535B (zh) * 2010-11-03 2012-12-19 北京天广实生物技术股份有限公司 新型抗ErbB2人源化抗体MIL12的制备及其应用
EP2643353A1 (fr) 2010-11-24 2013-10-02 Novartis AG Molécules multi-spécifiques
EP2655413B1 (fr) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Complexe polypeptide-polynucléotide et son utilisation dans l'administration d'une fraction effectrice ciblée
WO2012143524A2 (fr) 2011-04-20 2012-10-26 Genmab A/S Anticorps bispécifiques contre her2 et cd3
EP2744824A1 (fr) 2011-08-17 2014-06-25 F.Hoffmann-La Roche Ag Anticorps anti-neuréguline et utilisations associées
CN104024432B (zh) 2011-08-31 2017-02-22 基因泰克公司 诊断性标志物
IL301603A (en) 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (fr) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification de non-répondeurs aux inhibiteurs de her2
SG11201406079TA (en) 2012-03-27 2014-10-30 Genentech Inc Diagnosis and treatments relating to her3 inhibitors
EP2719706A1 (fr) 2012-10-15 2014-04-16 Universität Zürich Ligands de HER2 bispécifiques pour la thérapie du cancer
CA2883264A1 (fr) 2012-10-15 2014-04-24 Universitat Zurich Prorektorat Mnw Ligands her2 bispecifiques pour la therapie du cancer
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
CA3071678A1 (fr) 2013-04-16 2014-10-23 Genentech,Inc. Variantes de pertuzumab et leur evaluation
KR20160003141A (ko) 2013-05-01 2016-01-08 파이브 프라임 테라퓨틱스, 인크. 암을 치료하는 방법
AU2015249633B2 (en) 2014-04-25 2020-10-15 Genentech, Inc. Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
CN107614015A (zh) 2015-05-30 2018-01-19 豪夫迈·罗氏有限公司 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法
WO2017087280A1 (fr) 2015-11-16 2017-05-26 Genentech, Inc. Procédés de traitement d'un cancer positif her2
EP3454863A1 (fr) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Polythérapies pour le traitement du cancer
CN109843327B (zh) * 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
WO2018085513A1 (fr) 2016-11-04 2018-05-11 Genentech, Inc. Traitement du cancer du sein her2-positif
EP3562844A1 (fr) 2016-12-28 2019-11-06 Genentech, Inc. Traitement du cancer exprimant her2 avancé
KR20210134432A (ko) 2017-01-17 2021-11-09 제넨테크, 인크. 피하 her 2 항체 제형
EP3589661B1 (fr) 2017-03-02 2023-11-01 Genentech, Inc. Traitement par adjuvants du cancer du sein her2 positif
KR20190140952A (ko) 2017-04-24 2019-12-20 제넨테크, 인크. 막관통 및 인접막 도메인에서의 erbb2/her2 돌연변이
JP2019043214A (ja) 2017-08-30 2019-03-22 いすゞ自動車株式会社 ステアリング装置
CN112823168A (zh) 2018-10-08 2021-05-18 苏黎世大学 结合her2的四聚体多肽
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Preparations containing an antibody against HER2/NEU and their use

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US444960A (en) * 1891-01-20 Fence or gate
US4017471A (en) 1975-09-15 1977-04-12 G. D. Searle & Co. Immunological compounds
US4935341A (en) 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4994558A (en) 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
AU3568289A (en) 1988-04-18 1989-11-24 Applied Biotechnology, Inc. Detection of neu gene expression and products
JP2761543B2 (ja) 1988-08-17 1998-06-04 味の素株式会社 ヒト癌原遺伝子産物に対するモノクローナル抗体及びそれを産生するハイブリドーマ
DK0474727T3 (da) 1989-05-19 1998-01-12 Genentech Inc HER2 ekstracellulært domæne
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US6884418B1 (en) 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
DK0444181T3 (da) 1989-08-04 2002-02-25 Schering Ag C-erbB-2 eksternt domæne: gp75
JP2895105B2 (ja) 1989-09-14 1999-05-24 株式会社ニチレイ ｃ‐ｅｒｂＢ‐２癌遺伝子産物をイムノアッセイする乳癌の血清診断法とそのキット
JP3208427B2 (ja) 1989-09-29 2001-09-10 オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
CA2079585C (fr) 1990-04-06 1997-01-07 Mark I. Greene Ligand pour le produit du gene neu
US5578482A (en) 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
DK0517895T3 (da) 1990-12-14 1997-04-07 Univ California Kimæriske kæder til receptorforbundne signaltransduktionsveje
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5367060A (en) 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US5939531A (en) 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
US5514554A (en) 1991-08-22 1996-05-07 Becton Dickinson And Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
US5288477A (en) 1991-09-27 1994-02-22 Becton, Dickinson And Company Method for prognosticating response to cancer therapy
WO1994000136A1 (fr) 1992-06-30 1994-01-06 Oncologix, Inc. COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU3236793A (en) 1991-12-12 1993-07-19 Berlex Laboratories, Inc. Recombinant and chimeric antibodies to c-erbB-2
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
IT1257898B (it) * 1992-06-16 1996-02-16 Procedimento ed apparecchiatura per la produzione, in particolare domestica, di bevande.
AU5355594A (en) 1992-10-09 1994-05-09 Oncor, Inc. Methods for the detection of chromosome structural abnormalities by (in situ) hybridization to fixed tissue
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
CA2103323A1 (fr) 1992-11-24 1994-05-25 Gregory D. Plowman Tyrosine kinase du recepteur her4 humain
US5869445A (en) 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
DK0616812T3 (da) 1993-03-24 2000-04-25 Berlex Biosciences Kombination af antihormonforbindelser og bindingsmolekyler til behandling af cancer
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
US5430620A (en) 1993-10-08 1995-07-04 Cogent Light Technologies, Inc. Compact surgical illumination system capable of dynamically adjusting the resulting field of illumination
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
WO1995030331A1 (fr) 1994-05-05 1995-11-16 The Trustees Of The University Of Pennsylvania Compositions et procedes de traitement de tumeurs
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5846749A (en) 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
DE69504278T2 (de) 1994-11-10 1999-05-06 Univ Eberhard Karls Verfahren zur Wachstumshemmung von Leukämischen Zellen durch HER-2-Protein-Zeilen
WO1996016673A1 (fr) 1994-12-02 1996-06-06 Chiron Corporation Methode permettant d'induire une reponse immunitaire avec un anticorps bispecifique
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US5663144A (en) 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
JPH11507402A (ja) * 1995-05-26 1999-06-29 アイジェン・インコーポレーテッド 分子的にインプリントされた粒状ポリマー及び同ポリマーのペルフロオロカーボン液中における安定化懸濁重合
JP3354035B2 (ja) * 1995-05-31 2002-12-09 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料の処理方法
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
EP2258726A1 (fr) 1995-06-14 2010-12-08 The Regents of the University of California Anticorps humains à haute affinité pour c-erbB-2
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
EP0894139A1 (fr) 1996-03-20 1999-02-03 Board Of Regents The University Of Texas System Sensibilisation a la chimiotherapie de cellules cancereuses surexprimant la her-2/neu
US5925519A (en) 1996-06-03 1999-07-20 The Regents Of The University Of California Genetic alterations associated with prostate cancer
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
TR199901615T2 (en) 1996-10-18 1999-11-22 Genentech, Inc. Anti-ErbB2 antikorlar�.
WO1998018489A1 (fr) 1996-10-30 1998-05-07 The Uab Research Foundation Augmentation de la chimiosensibilite et de la radiosensibilite de cellules tumorales au moyen d'anticorps intracellulaires a une seule chaine
AU737910B2 (en) 1997-01-31 2001-09-06 Regents Of The University Of California, The Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
ES2308836T3 (es) 1998-03-27 2008-12-01 Genentech, Inc. Sinergia de los anticuerpos anti-her-2 y de los ligands para l'apo-2.
US6489447B1 (en) 1998-05-06 2002-12-03 Genentech, Inc. Protein purification
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6333348B1 (en) 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
EP1187632B1 (fr) 1999-05-14 2008-12-03 Genentech, Inc. TRAITEMENT AVEC DES ANTICORPS ANTI-ErbB2
EP1189634B1 (fr) 1999-06-25 2007-02-28 Genentech, Inc. Traitement du cancer de la prostate a l'aide des anticorps anti-erbb2
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
ATE438411T1 (de) * 1999-08-27 2009-08-15 Genentech Inc Dosierung für die behandlung mit anti erbb2- antikörpern
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
PL360153A1 (en) 2000-05-15 2004-09-06 Pharmacia & Upjohn S.P.A. Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
MXPA02011379A (es) 2000-05-19 2003-06-06 Genentech Inc Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb.
AU2002239486A1 (en) 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
CN100335132C (zh) 2001-01-09 2007-09-05 默克专利有限公司 含有受体酪氨酸激酶抑制剂和血管生成抑制剂的药物组合物及试剂盒
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
US20040258685A1 (en) 2002-11-21 2004-12-23 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
JP4969440B2 (ja) 2004-04-08 2012-07-04 デビッド， ビー． エイガス， 疼痛治療のためのＥｒｂＢアンタゴニスト
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
KR20120068807A (ko) 2004-07-22 2012-06-27 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101115849A (zh) 2004-12-07 2008-01-30 健泰科生物技术公司 选择her抑制剂疗法的患者
KR20170134771A (ko) 2005-01-21 2017-12-06 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
UA95902C2 (ru) * 2005-02-23 2011-09-26 Дженентек, Инк. Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
WO2006096861A2 (fr) 2005-03-08 2006-09-14 Genentech, Inc. Methodes permettant d'identifier des tumeurs sensibles au traitement par des inhibiteurs de dimerisation her (hdi)
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
BRPI0712077A2 (pt) 2006-05-01 2012-01-17 Genentech Inc prolongamento de sobrevivência de pacientes com cáncer com niveis elevados de egf ou tgf-alfa
JP5317084B2 (ja) 2006-11-08 2013-10-16 国立大学法人愛媛大学 π共役環状化合物およびその製造方法
ES2477497T3 (es) * 2007-03-02 2014-07-17 Genentech, Inc. Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo
JP5117165B2 (ja) 2007-11-09 2013-01-09 花王株式会社 水中油型乳化組成物の製造方法
JP5170667B2 (ja) 2008-06-02 2013-03-27 小林クリエイト株式会社 情報隠蔽帳票
BRPI0812682A2 (pt) * 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
JP5213775B2 (ja) 2009-03-25 2013-06-19 株式会社ジャパンディスプレイウェスト 電気光学装置および電子機器

Also Published As

Publication number Publication date
IL214084A0 (en) 2011-08-31
US20130209459A1 (en) 2013-08-15
CN1820734A (zh) 2006-08-23
KR20080075042A (ko) 2008-08-13
NO20002957L (no) 2000-08-11
KR20130036367A (ko) 2013-04-11
KR20150013870A (ko) 2015-02-05
US8642036B2 (en) 2014-02-04
JP2016006046A (ja) 2016-01-14
US8425908B2 (en) 2013-04-23
DK1037926T3 (en) 2014-03-03
KR20100135337A (ko) 2010-12-24
TR200001689T2 (tr) 2001-01-22
US20040037823A9 (en) 2004-02-26
ZA9811162B (en) 2000-06-07
JP2017039737A (ja) 2017-02-23
JP2002508397A (ja) 2002-03-19
JP2019055979A (ja) 2019-04-11
IL136201A (en) 2011-08-31
US20140341886A1 (en) 2014-11-20
JP2017165737A (ja) 2017-09-21
IL136201A0 (en) 2001-05-20
NO20091147L (no) 2000-08-11
WO1999031140A1 (fr) 1999-06-24
NO20002957D0 (no) 2000-06-09
US20050002928A1 (en) 2005-01-06
KR20120062942A (ko) 2012-06-14
US20190240185A1 (en) 2019-08-08
NZ504597A (en) 2003-05-30
BR9815363A (pt) 2001-10-16
US20030170234A1 (en) 2003-09-11
US8075892B2 (en) 2011-12-13
ES2450922T3 (es) 2014-03-25
AR020051A1 (es) 2002-04-10
KR20010033019A (ko) 2001-04-25
US8309087B2 (en) 2012-11-13
US20110250194A1 (en) 2011-10-13
JP2010209081A (ja) 2010-09-24
US20080187533A1 (en) 2008-08-07
US7892549B2 (en) 2011-02-22
JP2013056887A (ja) 2013-03-28
HK1091391A1 (en) 2007-01-19
HK1030784A1 (en) 2001-05-18
CA2730373A1 (fr) 1999-06-24
CN1820734B (zh) 2011-06-15
US20120034213A1 (en) 2012-02-09
AU1908199A (en) 1999-07-05
EP2277919A1 (fr) 2011-01-26
EP2275450A1 (fr) 2011-01-19
US7846441B1 (en) 2010-12-07
CN1281468A (zh) 2001-01-24
CA2311409C (fr) 2011-04-12
IL234696A (en) 2017-06-29
IL214084A (en) 2015-02-26
US20070292419A1 (en) 2007-12-20
US20030147884A1 (en) 2003-08-07
KR20180107323A (ko) 2018-10-01
EP1037926B1 (fr) 2014-01-15
CN1269839C (zh) 2006-08-16
EP1037926A1 (fr) 2000-09-27

Similar Documents

Publication Publication Date Title
CA2311409A1 (fr) Traitement aux anticorps anti-erbb2
Gong et al. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines
Prewett et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts
Gan et al. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy
Lee et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma
Merlin et al. In vitro comparative evaluation of trastuzumab (Herceptin®) combined with paclitaxel (Taxol®) or docetaxel (Taxotere®) in HER2-expressing human breast cancer cell lines
US20150079080A1 (en) Novel anti-igf-ir antibodies and uses thereof
Kok et al. Expression of Cyr61 (CCN1) in human oral squamous cell carcinoma: An independent marker for poor prognosis
WO2002045653A3 (fr) Radiotherapie et chimiotherapie combinees avec l'administration d'un anticorps du recepteur du facteur de croissance
Georgieva et al. ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio-and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines
HUP0102992A3 (en) Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis
NZ296638A (en) Ligands which bind to tie-2 (tyrosine kinase with ig and egf homology domains) receptors
JP2008504227A (ja) 癌疾患修飾抗体
Wood et al. Initial testing (Stage 1) of the antibody‐maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program
JP2008504226A (ja) 癌疾患修飾抗体
Hartimath et al. Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft
Modjtahedi Molecular therapy of head and neck cancer
Chung et al. PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations
Takahashi et al. HER2 targeting near‐infrared photoimmunotherapy for a CDDP‐resistant small‐cell lung cancer
Rait et al. HER‐2‐targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents
Van Gog et al. Perspectives of combined radioimmunotherapy and anti‐EGFR antibody therapy for the treatment of residual head and neck cancer
FI982745A (fi) TIE-2-reseptoriligandit (TIE-ligandi-3; TIE-ligandi-4) ja niiden käytt"
O'dwyer Axillary dissection in primary breast cancer.
Luca et al. Peptide ligands specifically targeting HER2 Receptor and the role played by a synthetic model system of the receptor extracellular domain: Hypothesized future perspectives
Choi et al. Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20181210